Encephalitis clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Orange, California and other locations
Our lead scientists for Encephalitis research studies include Xiao-Tang Kong, MD.